NRX Pharmaceuticals, Inc. (NRXP)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, NRX Pharmaceuticals, Inc. reported revenue of $1.45M. The company ran a net loss, with a net margin of -1980.8%. It held $12.96M in total assets against $28.89M in total liabilities.
Key ratios (FY2025)
-1122.8%
Operating margin
-1980.8%
Net margin
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.45M | $0 | $0 | — | — | — | — | — | — |
| Cost of Revenue | $505.0K | $0 | — | — | — | — | — | — | — |
| Operating Income | -$16.22M | -$18.50M | -$27.84M | -$44.34M | -$115.80M | -$51.39M | -$713.2K | -$1.01M | — |
| Net Income | -$28.62M | -$25.13M | -$30.15M | -$39.75M | -$93.06M | -$51.78M | $408.4K | $66.1K | — |
| EPS (Diluted) | $-1.34 | $-2.36 | $-3.98 | $-0.60 | $-1.98 | $-1.51 | — | — | — |
| Total Assets | $12.96M | $3.65M | $7.32M | $25.82M | $32.73M | $2.94M | $32.07M | $70.80M | $69.57M |
| Total Liabilities | $28.89M | $26.87M | $19.05M | $18.41M | $11.92M | $46.71M | $2.57M | $1.26M | $93.2K |
| Shareholders' Equity | -$15.94M | -$23.22M | -$11.73M | $7.41M | $20.81M | -$43.77M | -$4.84M | $5.00M | $5.00M |
| Cash & Equivalents | $7.80M | $1.44M | $4.59M | $20.05M | $27.61M | — | — | — | — |
| Operating Cash Flow | -$14.11M | -$10.64M | -$21.66M | -$39.76M | -$37.70M | -$2.27M | -$792.7K | -$473.2K | — |
| Capital Expenditures | — | $0 | $3.0K | $10.0K | $7.0K | $2.0K | — | — | — |
| Shares Outstanding | 31.73M | 14.59M | 8.39M | 66.44M | 58.81M | 42.97M | 2.84M | 2.73M | 2.59M |